Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | PRKDC | P78527 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087809 | 0.85 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL210330 | 0.80 | ALDH1A1 (0.68) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL29800558 | 0.80 | ALDH1A1 (0.68) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL10778338 | 0.80 | ALDH1A1 (0.62) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL28620392 | 0.79 | ALDH1A1 (0.58) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL6370055 | 0.78 | ALDH1A1 (0.57) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL28196003 | 0.78 | TUBB4A (0.51) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL95595 | 0.78 | ALDH1A1 (0.56) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL11135612 | 0.77 | ALDH1A1 (0.58) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL19083207 | 0.76 | ATM (0.40) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1014 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891668-B2 | Methods for generating therapeutic delivery platforms | THE UNIVERSITY OF KANSAS (US) | 2024-02-06 | — | — | US | claimed |
| US-20230373962-A1 | SUPRAMOLECULAR MOLECULES FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF BIRMINGHAM (GB) | 2023-11-23 | — | — | US | claimed |
| CN-115350659-A | Method for preparing capsules sensitive to pH or ultraviolet radiation and capsules obtained thereby | 卡莉西亚公司 | 2022-11-18 | — | — | CN | claimed |
| CN-111344057-B | Method for preparing capsules sensitive to pH or ultraviolet radiation and capsules obtained thereby | 卡莉西亚公司 | 2022-09-27 | — | — | CN | claimed |
| WO-2022064066-A1 | SUPRAMOLECULAR MOLECULES FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF BIRMINGHAM (GB) | 2022-03-31 | — | — | WO | claimed |
| CN-107002293-B | Sequencing by synthesis using pulsed readout optics | 艾比斯生物科学公司 | 2020-12-08 | — | — | CN | claimed |
| CN-111344057-A | Method for preparing capsules sensitive to pH or ultraviolet radiation and capsules obtained thereby | 卡莉西亚公司 | 2020-06-26 | — | — | CN | claimed |
| US-20200123605-A1 | SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS | IBIS BIOSCIENCES, INC. | 2020-04-23 | — | — | US | claimed |
| EP-3194643-B1 | SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS | IBIS BIOSCIENCES INC (US) | 2020-02-19 | — | — | EP | claimed |
| US-10550428-B2 | Sequencing by synthesis using pulse read optics | IBIS BIOSCIENCES, INC. (US) | 2020-02-04 | — | — | US | claimed |
| EP-0619321-A1 | Very large scale immobilized peptide synthesis | AFFYMAX TECHNOLOGIES N.V. (AN) | 1994-10-12 | — | — | EP | claimed |
| EP-0476014-B1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECH NV (AN) | 1994-08-31 | — | — | EP | claimed |
| WO-1993022680-A1 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF OLIGONUCLEOTIDES AND OTHER BIOLOGICAL POLYMERS ON SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-11-11 | — | — | WO | claimed |
| US-5252743-A | Using cage binding compound | AFFYMAX TECHNOLOGIES N.V. (NL) | 1993-10-12 | — | — | US | claimed |
| EP-0502060-A4 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF ANTI-LIGANDS ON SURFACES | — | 1993-05-05 | — | — | EP | claimed |
| EP-0502060-A1 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF ANTI-LIGANDS ON SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-09-09 | — | — | EP | claimed |
| US-5143854-A | LARGE SCALE PHOTOLITHOGRAPHIC SOLID PHASE SYNTHESIS OF POLYPEPTIDES AND RECEPTOR BINDING SCREENING THEREOF | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-09-01 | — | — | US | claimed |
| EP-0476014-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS. | AFFYMAX TECH NV (NL) | 1992-03-25 | — | — | EP | claimed |
| WO-1991007087-A1 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF ANTI-LIGANDS ON SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1991-05-30 | — | — | WO | claimed |
| WO-1990015070-A1 | VERY LARGE SCALE IMMOBILIZED PEPTIDE SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1990-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373962-A1 | SUPRAMOLECULAR MOLECULES FOR THE TREATMENT OF CANCER | PCNA, DDX1, DDX18 | ALDH1A1 4454/4885MAPT 3449/4885KDM4E 3147/4885 |
| US-11891668-B2 | Methods for generating therapeutic delivery platforms | EXOSC4, EXOSC5, EXOSC9 | ALDH1A1 2893/4885MAPT 612/4885KDM4E 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.